1. Department of Medicine III, University Hospital, LMU Munich, Munich, Germany;
2. Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany;
3. Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland;
4. Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland;
5. Research Unit Apoptosis in Hematopoietic Stem Cells (AHS), Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany;
6. Unit of Immunogenetics, Leukemia Genomics and Immunobiology, IRCCS San Raffaele Scientific Institute, Milan, Italy;
7. Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany;
8. Nimble Therapeutics, Madison, WI;
9. Institute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany;
10. National Center for Tumor Diseases, Partner Site Dresden, Dresden, Germany;
11. German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany;
12. Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy;
13. German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany; and
14. Department of Pediatrics, Dr von Hauner Children’s Hospital, Ludwig Maximilian University (LMU), Munich, Germany